Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | PGD | P52209 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4871828 | 1.00 | SUCNR1 (0.38) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL2032406 | 1.00 | SUCNR1 (0.38) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL14527074 | 1.00 | SUCNR1 (0.38) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL15325118 | 1.00 | SUCNR1 (0.38) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL27159744 | 0.85 | SUCNR1 (0.45) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL1595064 | 0.85 | SUCNR1 (0.45) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL1727954 | 0.85 | SUCNR1 (0.45) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL1595065 | 0.85 | SUCNR1 (0.45) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL10473227 | 0.85 | SUCNR1 (0.45) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL14944924 | 0.81 | MAPK1 (0.37) | MAPK1NPSR1GAAPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299342-B1 | METHOD FOR PRODUCING 3,3-DIARYLPROPYLAMINES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-05-02 | — | — | EP | claimed |
| US-6809225-B2 | BY HYDROCARBONYLATION/HYDROFORMYLATION WITH SUBSEQUENT REDUCTIVE AMINATION | SCHWARZ PHARMA AG (DE) | 2004-10-26 | — | — | US | claimed |
| US-8518966-B2 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2185553-B1 | AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7902221-B2 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090062335-A1 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE, INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062335-A1 | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRL1, OPRK1 | SUCNR1 629/4885MAPK1 694/4885NPSR1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.